de Faire U, Forslund L, Odén A
Acta Med Scand. 1986;220(5):411-8. doi: 10.1111/j.0954-6820.1986.tb02789.x.
The antihypertensive effects of verapamil over 24 hours were assessed on twice and thrice daily dose regimens on 12 patients (25-65 years of age; mean age 50) with essential hypertension (WHO stages I-II) in a randomised, double-blind, cross-over trial. After a dose titration period starting with either verapamil 80 mg tid or 120 mg bid the patients kept their maintenance dose (240, 360 or 480 mg daily) for 4 weeks before crossing over to the other administration schedule. Repeated ambulatory blood pressure (BP) curves were recorded in 10 patients with a non-invasive portable device (Pressurometer III, Del Mar Avionics). The BP reductions (causal BP values) obtained by 2- and 3-dose regimens were of similar magnitude (from 170 +/- 19/105 +/- 8 on placebo to 140 +/- 17/87 +/- 7 and to 146 +/- 14/88 +/- 8 by 2-and 3-dose respectively). Analyses of BP curves revealed close similarity in profiles on the two dose regimens, although DBP was significantly (p less than 0.05) lower by 3-dose as compared to 2-dose regimen during the period 0.00-2.59 a.m. Long-term (circadian rhythm) and short-term variability did not differ between the regimens. Despite the slight difference in DBP curves after midnight, the overall impression is that verapamil given both twice and thrice daily provides adequate BP control throughout 24 hours.
在一项随机、双盲、交叉试验中，对12例（年龄25 - 65岁，平均年龄50岁）患有原发性高血压（WHO分期I - II期）的患者，评估了维拉帕米每日两次和每日三次给药方案的24小时降压效果。在以维拉帕米80毫克每日三次或120毫克每日两次开始的剂量滴定期后，患者维持其维持剂量（每日240、360或480毫克）4周，然后转换到另一种给药方案。使用无创便携式设备（Pressurometer III，德尔马航空电子公司）对10例患者记录重复的动态血压（BP）曲线。两剂量和三剂量方案获得的血压降低（因果血压值）幅度相似（安慰剂组为170±19/105±8，两剂量组为140±17/87±7，三剂量组为146±14/88±8）。血压曲线分析显示两种剂量方案的曲线轮廓非常相似，尽管在凌晨0.00 - 2.59期间，三剂量方案的舒张压（DBP）比两剂量方案显著降低（p < 0.05）。两种方案之间的长期（昼夜节律）和短期变异性没有差异。尽管午夜后舒张压曲线存在轻微差异，但总体印象是，维拉帕米每日两次和每日三次给药在24小时内均能提供充分的血压控制。
